SCHEMBL4870980

SCHEMBL4870980

O=C1C(NS(=O)(=O)c2ccccc2)Cc2cc(-c3ccccc3)cnc2N1Cc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
F10 P00742 7/20 0.41
PIK3CD O00329 3/20 0.40
NPY1R P25929 1/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CB P42338 1/20 0.40
PIK3CG P48736 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
HTR1A P08908 1/20 0.37
HTR7 P34969 1/20 0.37
F2 P00734 2/20 0.37
ALDH1A1 P00352 2/20 0.36
MAPT P10636 1/20 0.36
NR1I2 O75469 1/20 0.36
POLB P06746 1/20 0.35
HTT P42858 1/20 0.35
MTOR P42345 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5655084 0.82 NPY1R (0.47) F10NPY1RSMN1; SMN2MEN1KMT2A
SCHEMBL10183595 0.82 NPY1R (0.47) F10NPY1RSMN1; SMN2MEN1KMT2A
SCHEMBL4870965 0.81 NPY1R (0.43) F10NPY1RSMN1; SMN2MEN1KMT2A
SCHEMBL4876088 0.79 FNTA (0.44) F10PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL4876140 0.79 AADAT (0.46) MEN1KMT2AALDH1A1
SCHEMBL5134064 0.77 NPY1R (0.54) NPY1RSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL4802349 0.76 NPY1R (0.45) F10NPY1RSMN1; SMN2MEN1KMT2A
SCHEMBL5133148 0.74 NPY1R (0.47) F10NPY1RSMN1; SMN2MEN1KMT2A
SCHEMBL649727 0.74 ALDH1A1 (0.48) F10NPY1RSMN1; SMN2MEN1KMT2A
SCHEMBL5132775 0.74 ALDH1A1 (0.48) F10NPY1RSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368458-B2 Bicyclic heterocycles as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-06 US disclosed
US-7368458-B2 Bicyclic heterocycles as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-06 US disclosed
WO-2006076597-A1 BICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-07-20 WO disclosed
US-20060155126-A1 Bicyclic heterocycles as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY 2006-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060155126-A1 Bicyclic heterocycles as cannabinoid receptor modulators CNR1, CNR2, GPR18 F10 1295/4885PIK3CD 1268/4885NPY1R 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.